

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (original): A pharmaceutical formulation containing paraoxonase (PON), which contains PON and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS).

Claim 2 (original): The pharmaceutical formulation according to claim 1, which further contains a polyol.

Claim 3 (original): The pharmaceutical formulation according to claim 2, wherein the polyol is glycerol.

Claim 4 (original): A method for purifying PON, which comprises subjecting a solution containing PON to a hydrophobic carrier treatment and then to an anion exchanger treatment in the presence of CHAPS.

Claim 5 (original): The purification method according to claim 4, wherein the anion exchanger treatment is performed in the presence of CHAPS and a polyol.

Claim 6 (original): The purification method according to claim 5, wherein the polyol is glycerol.

Claim 7 (original): A method for stabilizing PON, which comprises adding CHAPS to PON.

Claim 8 (original): The stabilization method according to claim 7, which further comprises adding a polyol.

Claim 9 (original): The stabilization method according to claim 8, wherein the polyol is glycerol.

Claim 10 (original): An agent for prophylactic and/or therapeutic treatment of a disease resulting from ischemia reperfusion and/or cerebral infarction, which comprises PON as an active ingredient.

Claim 11 (original): The agent for prophylactic and/or therapeutic treatment according to claim 10, which is used for improving prognosis, neurological symptoms, or motor dysfunction of a disease resulting from ischemia reperfusion and/or cerebral infarction.

Claim 12 (original): An agent for prophylactic and/or therapeutic treatment of a disease resulting from ischemia reperfusion and/or cerebral infarction, which comprises PON and CHAPS.

Claim 13 (original): The agent according to claim 12, which is used for improving prognosis, neurological symptoms or motor dysfunction of a disease resulting from ischemia reperfusion and/or cerebral infarction.

Claim 14 (original): The agent according to claim 12 or 13, which further comprises a polyol.

Claim 15 (original): The agent according to claim 14, wherein the polyol is glycerol.

Claim 16 (currently amended): A method for improving prognosis, neurological symptoms, or motor dysfunction of a disease resulting from ischemia reperfusion and/or cerebral infarction, ~~which comprises~~ comprising:

administering an effective amount of [[PON]] paraoxonase to improve one of prognosis, neurological symptoms and motor dysfunction of a disease resulting from at least one of ischemia reperfusion and cerebral infarction.

Claim 17 (canceled)

Claim 18 (new): The method of claim 16, wherein the administering of the effective amount of paraoxonase comprises administering an effective amount of 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate in combination.

Claim 19 (new): The method of claim 18, wherein the administering of the effective amount of paraoxonase comprises administering the effective amount of paraoxonase in the presence of a polyol.

Claim 20 (new): The method of claim 19, wherein the polyol is glycerol.